

## EMAP-II, Human

**Cat. No.:** Z02732-1

**Size:** 1.0 mg

**Synonyms:** Endothelial-Monocyte A Activating Polypeptide II (EMAP-II), Human;

### Description:

EMAP-II is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.

### Amino Acid Sequence:

```
00001 SKPIDVSRDL LRIGCIITAR KHPDADSLYV EEVDVGEIAP
00041 RTVVSGLVNH VPLEQMQRNM VILLCNLKPA KMRGVLSQAM
00081 VMCASSPEKI EILAPPNGSV PGDRITFDFAF PGEPAKELNP
00121 KKKIWEQIQP DLHTNDECVA TYKGVPFVVK GKVCRAQTM
00161 SNSGIK
```

**Source:** *E. coli*

**Species:** Human

**Biological Activity:** Fully biologically active when compared to standard. The ED<sub>50</sub> as determined by the apoptotic effect using serum free human MCF-7 cells is less than 40 ng/ml, corresponding to a specific activity of > 2.5 × 10<sup>4</sup> IU/mg.

**Molecular Weight:** Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.

**Formulation:** Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

**Appearance:** Sterile Filtered White lyophilized (freeze-dried) powder.

**Reconstitution:** We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

**Purity:** > 98 % by SDS-PAGE and HPLC analyses.

**Endotoxin Level:** Less than 1 EU/μg of rHuEMAP-II as determined by LAL method.

**Storage:** This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.